Hematology

Clinical pharmacy services in hematology can have a significant impact, and the Pharmacy Times® Hematology resource center provides clinical news and articles about the topic. Here, visitors will find information about upcoming hematology conferences and meetings, updated clinical trial listings, and other resources.

What can we help you find?
[[thumbnail_alt_text]]
Further, these natural killer (NK) cells appear to be more effective the earlier they are in development, creating the possibility of an immunotherapy that would not use cells from a patient or a matched donor.
[[thumbnail_alt_text]]
The phase 3 trial showed a statistically significant improvement in overall survival (OS) and composite complete remission rate.
 
[[thumbnail_alt_text]]
A bipartisan coalition in Congress has introduced new legislation designed to ensure Medicare patients have access to Part B home infusion medications.
[[thumbnail_alt_text]]
Treatment with cord blood-derived chimeric antigen receptor natural killer-cell therapy targeting CD19 resulted in clinical responses in relapsed or refractory non-Hodgkin’s lymphoma and chronic lymphocytic leukemia.
[[thumbnail_alt_text]]
A study offers evidence that chimeric antigen receptor T-cell therapy may not only extend patients’ survival, but also improve their quality of life after treatment.
[[thumbnail_alt_text]]
The drug also received orphan drug designation.
 
[[thumbnail_alt_text]]
Many people are unaware that acute myeloid leukemia (AML) is the leading cause of acute leukemia in adults. 
[[thumbnail_alt_text]]
Two recently approved leukemia drugs could be enlisted against treatment-resistant lung cancer.
[[thumbnail_alt_text]]
CAR NK cells are allogenic, which is defined as taking the cells from a non-related healthy donor rather than the patient themselves. Therefore, CAR NK cells have the potential to be manufactured in advance and stored for off-the-shelf immediate use. 
[[thumbnail_alt_text]]
Research may help to develop usable hematopoietic stem cells that could regrow a patient with leukemia’s blood system after chemotherapy and irradiation.
[[thumbnail_alt_text]]
Valoctocogene roxaparvovec (Valrox, BioMarin Pharmaceutical Inc) would be the first gene therapy in the United States for the most common form of hemophilia if approved by the FDA.1
[[thumbnail_alt_text]]
Belantamab mafodotin has the potential for durable responses in patients with multiple myeloma whose disease has relapsed or is resistant to standard therapies.